ProCE Banner Series

Advances in Chronic Lymphocytic Leukemia: A Master Class for the Community Multidisciplinary Team

Register now for this interactive, case-based workshop series to hear about how to effectively incorporate newly approved and emerging agents and treatment combinations into the care of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). After the meeting, download the associated slideset for use in your clinic. 

  ACPE
  | AMA
  | ANCC
Who Should Attend

This program is intended for community-based medical hematologists/oncologists, nurses, pharmacists, advanced practice providers, and other healthcare professionals involved in the treatment of patients with CLL.

All Events

Past Events

January

12

2023

Advances in Chronic Lymphocytic Leukemia: A Master Class for the Community Multidisciplinary Team

7:00 PM - 8:00 PM Pacific Time (PT)

Virtual

Private Event, Fremont, California

January

19

2023

Advances in Chronic Lymphocytic Leukemia: A Master Class for the Community Multidisciplinary Team

6:30 PM - 8:00 PM Central Time (CT)

Virtual

Private Event -- Advocate Aurora Health

February

15

2023

Advances in Chronic Lymphocytic Leukemia: A Master Class for the Community Multidisciplinary Team

4:30 PM - 5:30 PM Central Time (CT)

Virtual

Private Event -- Norman Regional Oncology

February

23

2023

Advances in Chronic Lymphocytic Leukemia: A Master Class for the Community Multidisciplinary Team

8:00 AM - 9:00 AM Eastern Time (ET)

Virtual

Private Event -- Bennington, VT

March

06

2023

Advances in Chronic Lymphocytic Leukemia: A Master Class for the Community Multidisciplinary Team

7:30 AM - 8:30 AM Central Time (CT)

Virtual

Private Event, Birmingham, Alabama

March

16

2023

Advances in Chronic Lymphocytic Leukemia: A Master Class for the Community Multidisciplinary Team (Private)

10:00 AM - 11:00 AM Eastern Time (ET)

In-personVirtual

Private Event, Staten Island, New York

March

25

2023

Advances in Chronic Lymphocytic Leukemia: A Master Class for the Community Multidisciplinary Team

10:30 AM - 11:30 AM Pacific Time (PT)

In-person

Private Event, Las Vegas, Nevada

March

28

2023

Advances in Chronic Lymphocytic Leukemia: A Master Class for the Community Multidisciplinary Team

4:00 PM - 5:00 PM Mountain Time (MT)

Virtual

Private Event, Rio Rancho, New Mexico

March

29

2023

Advances in Chronic Lymphocytic Leukemia: A Master Class for the Community Multidisciplinary Team

6:30 PM - 7:30 PM Eastern Time (ET)

In-person

Private Event, Pembroke Pines, Florida

April

04

2023

Advances in Chronic Lymphocytic Leukemia: A Master Class for the Community Multidisciplinary Team

6:30 PM - 7:30 PM Eastern Time (ET)

Virtual

Private Event, New Hyde Park, New York

April

06

2023

Advances in Chronic Lymphocytic Leukemia: A Master Class for the Community Multidisciplinary Team [Open Registration]

11:30 AM - 12:30 PM Central Time (CT)

Virtual

CCO Simulcast | Host Group TX, Kyle, Texas

April

06

2023

Advances in Chronic Lymphocytic Leukemia: A Master Class for the Community Multidisciplinary Team

12:30 PM - 1:30 PM Eastern Time (ET)

Virtual

Private Event, Rockville, Maryland

April

12

2023

Advances in Chronic Lymphocytic Leukemia: A Master Class for the Community Multidisciplinary Team [Open Registration]

8:00 AM - 9:00 AM Eastern Time (ET)

Virtual

CCO Simulcast | Host Group NJ, Elizabeth, New Jersey

April

18

2023

Advances in Chronic Lymphocytic Leukemia: A Master Class for the Community Multidisciplinary Team

6:00 PM - 7:00 PM Pacific Time (PT)

Virtual

Private Event | Post Falls, Post Falls, Idaho

April

21

2023

Advances in Chronic Lymphocytic Leukemia: A Master Class for the Community Multidisciplinary Team

11:00 AM - 12:00 PM Mountain Time (MT)

Virtual

Private Event, Colorado Springs, Colorado

April

27

2023

Advances in Chronic Lymphocytic Leukemia: A Master Class for the Community Multidisciplinary Team [Open Registration]

12:00 PM - 1:00 PM Eastern Time (ET)

Virtual

CCO Simulcast | Host Group MI, Royal Oak, Michigan

May

02

2023

Advances in Chronic Lymphocytic Leukemia: A Master Class for the Community Multidisciplinary Team

9:00 AM - 10:00 AM Mountain Time (MT)

Virtual

Private Event, Boise, Idaho

May

09

2023

Advances in Chronic Lymphocytic Leukemia: A Master Class for the Community Multidisciplinary Team

6:00 PM - 7:00 PM Eastern Time (ET)

Virtual

Private Event, Wall Township, New Jersey

May

11

2023

Advances in Chronic Lymphocytic Leukemia: A Master Class for the Community Multidisciplinary Team

12:00 PM - 1:00 PM Central Time (CT)

Virtual

Private Event, Mobile, Alabama

May

30

2023

Advances in Chronic Lymphocytic Leukemia: A Master Class for the Community Multidisciplinary Team

6:00 PM - 7:00 PM Eastern Time (ET)

Virtual

Private Event | Host Group at The Hackney, Washington, North Carolina

June

14

2023

Advances in Chronic Lymphocytic Leukemia: A Master Class for the Community Multidisciplinary Team

8:30 AM - 9:30 AM Eastern Time (ET)

Virtual

Private Event | Virtual Group, Hendersonville, North Carolina

June

15

2023

Advances in Chronic Lymphocytic Leukemia: A Master Class for the Community Multidisciplinary Team

4:30 PM - 5:30 PM Central Time (CT)

Virtual

Private Event | Virtual Group, Dallas, Texas

June

21

2023

Advances in Chronic Lymphocytic Leukemia: A Master Class for the Community Multidisciplinary Team

11:30 AM - 12:30 PM Central Time (CT)

Virtual

Private Event | Virtual Group, Decatur, Texas

June

29

2023

Advances in Chronic Lymphocytic Leukemia: A Master Class for the Community Multidisciplinary Team

6:00 PM - 7:00 PM Central Time (CT)

In-personVirtual

Private Event | Host Group at Walker's, Jackson, Mississippi

Faculty

ProCE Banner Faculty
Farrukh Awan, MD, MS

Associate Professor of Internal Medicine
Division of Hematology
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

ProCE Banner Faculty
Farrukh T. Awan, MD, MS, MBA

Associate Director, Section of Hematologic Malignancies/Transplantation and Cellular Therapy
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

ProCE Banner Faculty
Danielle M. Brander, MD

Medical Instructor
Division of Hematologic Malignancies & Cellular Therapy
Department of Medicine
Duke University
Attending Physician, Hematologic Malignancies
Duke University Health System
Durham, North Carolina

ProCE Banner Faculty
Danielle M. Brander, MD

Assistant Professor of Medicine
Division of Hematologic Malignancies and Cellular Therapy
Duke Cancer Institute
Durham, North Carolina

ProCE Banner Faculty
Jennifer R. Brown, MD, PhD

Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology
Harvard Medical School
CLL Center Director and Institute Physician
Dana-Farber Cancer Institute
Boston, Massachusetts

ProCE Banner Faculty
Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

ProCE Banner Faculty
Jeff DONOTUSESharman, MD

Medical Director of Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

ProCE Banner Faculty
Nicole Lamanna, MD

Judy Horrigan Professor of Medicine, Leukemia Service
Director of the Chronic Lymphocytic Leukemia Program
Hematologic Malignancies Section
Herbert Irving Comprehensive Cancer Center
NewYork-Presbyterian/Columbia University Medical Center
New York, New York

ProCE Banner Faculty
Susan M. O'Brien, MD

Professor
Division of Hematology/Oncology
School of Medicine
University of California, Irvine
Orange, California

ProCE Banner Faculty
Nirav Shah, MD

Associate Professor of Medicine
Division of Hematology and Oncology
Medical College of Wisconsin
Milwaukee, Wisconsin

Topics

• Introduction

• Case Discussions: Individualizing Care of Patients with CLL/SLL

- Key Variables in Making Treatment Decisions
- Classes of Agents: Mechanism of Action, Selectivity, Specificity and Associated Adverse Events
- Recent Data on Advances in the Treatment of CLL/SLL
- Optimal and effective management of CLL/SLL

• Partnering With Patients in Their Care

- Discussing Patient Treatment Goals and Expectations
- Best Practices in Patient Care
- Effective Communication of New or Worsening Symptoms with Healthcare Professionals

• Final Thoughts and Audience Question and Answer Session

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact meetings@clinicaloptions.com prior to the live event.

CME/CE Info

Program Overview
This program will provide expert perspectives to facilitate state-of-the-art clinical management strategies for patients with CLL/SLL, including information on the latest practice impacting data on recent advances in the personalization of care for patients with CLL/SLL.

Goal Statement
The goal of this program is to improve the knowledge, confidence, and competence of multidisciplinary team learners in the care of patients with CLL using evidence-based and guideline-directed best practices.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Plan therapeutic approaches for treatment-naive and relapsed/refractory CLL/SLL, taking into consideration available clinical data, the agent’s toxicity profile, prognostic variables, comorbidities, and patient preference
  • Appraise the differences in selectivity, binding, efficacy, and adverse event profiles of agents with a similar molecular target used to treat CLL/SLL
  • Develop multidisciplinary management plans for patients with CLL/SLL to optimize quality of life and address racial-related and age-related disparities in care
  • Manage treatment-related symptoms in patients with CLL/SLL using guidelines and expert recommendations based on real-world experience to optimally adjust, discontinue, or change the patient’s current therapeutic plan 
  • Evaluate the evolving role of measurable/minimal residual disease, allogeneic hematopoietic cell transplant, CAR T-cell therapy, and other novel therapeutics for CLL/SLL

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-23-012-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC

Supported by educational grants from AbbVie Inc.; AstraZeneca Pharmaceuticals; Genentech, a member of the Roche Group; and Lilly.